Screening to improve early detection of pancreatic cancer in high-risk adults
Official title: MC250406 Feasibility Study: Automated Risk Stratification, Serial AI-Augmented Imaging, and Biobanking for Early Detection of Sporadic Pancreatic Cancer (AI-PACED)
Run by Mayo Clinic · NCT07324096 · Data updated 2026-11-12
This program tests whether repeated contrast-enhanced CT scans combined with blood draws and AI can find pancreatic cancer earlier in people aged 50–85 with recent-onset diabetes and a high ENDPAC score.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 85 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | March 24, 2026 |
| Main results expected | March 24, 2029 |
| Study ends | March 24, 2029 |
| Registry record updated | October 14, 2026 |
| Trial ID | NCT07324096 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 50 to 85 years old with glycemically-defined new-onset diabetes within the past 180 days and an ENDPAC score ≥ 3 who can undergo contrast-enhanced CT and provide consent.
✕Probably not a fit
People with a prior pancreatic cancer diagnosis, known hereditary cancer syndromes, prior pancreatic surgery, current pancreatic cyst surveillance, contraindications to contrast CT, or those outside the age or new-onset diabetes window are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The program enrolls adults aged 50–85 with glycemically-defined new-onset diabetes (onset within 180 days) and an ENDPAC score of 3 or higher to undergo repeated contrast-enhanced CT imaging, blood collection, and AI-assisted image review. Imaging is read by radiologists and processed by AI algorithms while blood samples are used for biomarker analysis and biobanking. People with prior pancreatic cancer, known hereditary cancer syndromes, prior pancreatic surgery, current pancreatic cyst surveillance, or contraindications to contrast CT are excluded. The work is based at Mayo Clinic in Rochester and aims to create a practical surveillance pathway to detect sporadic pancreatic cancer earlier in a defined high-risk group.
Why it matters
Potential benefit: If successful, this approach could detect pancreatic cancer earlier in high-risk people, improving the chance of curative treatment and better survival.
How similar studies have gone: Risk models like ENDPAC have been validated to identify higher-risk patients, but combining repeated contrast CT, AI image analysis, and blood biomarkers in glycemically-defined new-onset diabetes is a relatively novel approach without established outcome-proof in this exact setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 50 and ≤ 85 years * Glycemically-defined new-onset diabetes (gNOD) with onset ≤ 180 days preceding enrollment * Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3, based on validated risk stratification models * Provide written or remote informed consent Exclusion Criteria: * Prior diagnosis of pancreatic ductal adenocarcinoma (PDA) * Known hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome, Peutz-Jeghers) * Prior history of pancreatic surgery * Pancreatic cyst surveillance at time of registration * Contraindications to contrast-enhanced CT imaging per standard clinical practice at time of registration
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Ajit H. Goenka, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers
This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.
-
GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC
This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.
-
First-in-human test of BLU-924 for KRAS-mutant advanced cancers
This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.